Corey McCann
Pear Therapeutics

Corey M McCann M.D., Ph.D. is the President and CEO of Pear Therapeutics, a company developing prescription digital therapeutics and drug/software combinations for treatment of severe medical conditions.

Previously, he was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system (CNS) expertise group, advising clients across the healthcare value chain. Corey has previous investment experience with RiverVest Venture Partners, where he performed diligence on early stage investments, and at NeuroInsights, where he evaluated brain related technologies. Corey is also a co-founder, advisor, or Board Director at AgNovos Healthcare, Alcyone Lifesciences, Dragonfly Sciences, Edumedics, Eternia Group, New Frontier Bio, Rapid Pharmaceuticals AG, Resolute Bio, Selexys Pharmaceuticals, and Zillion Health.

Dr. McCann trained as a physician-scientist via the Medical Scientist Training Program. For his PhD, he studied the molecular biology of synapses at Harvard University and at Washington University in St Louis. He was also a post-doctoral researcher at the Massachusetts General Hospital where he developed imaging techniques for the visualization of the brain.

Dr. McCann received his M.D. from Washington University in St. Louis. He graduated summa cum laude from The Pennsylvania State University where he was an Evan Pugh Scholar, receiving a B.S. in Biology with minors in neuroscience, biochemistry, and molecular biology.